logo
Science Portal
Copyright © Médecins Sans Frontières
v2.1.5153.produswest2
About MSF Science Portal
About
Contact Us
Frequently Asked Questions (FAQs)
Privacy Policy
Terms of Use
Copyright © Médecins Sans Frontières
v2.1.5153.produswest2
Prevalence and outcomes of antibiotic resistant infections at MSF projects | Collections | MSF Science Portal
Prevalence and outcomes of antibiotic resistant infections at MSF projects

Prevalence and outcomes of antibiotic resistant infections at MSF projects

Collection Content

Journal Article
|
Research

Faecal carriage of extended-spectrum ß-lactamase-producing Escherichia coli in a remote region of Niger

Jacquier H, Assao B, Chau F, Guindo O, Condamine B,  et al.
2023-06-25 • Journal of Infection
2023-06-25 • Journal of Infection
OBJECTIVE
Whole genome sequencing (WGS) of extended-spectrum ß-lactamase-producing Escherichia coli (ESBL-E. coli) in developing countries is lacking. Here we describe the population...
Conference Material
|
Abstract

Invasive bacterial infections in patients with advanced HIV disease in Kinshasa: prevalence, antibiotic resistance and treatment

Langendorf C
2023-06-08 • Epicentre Scientific Day Paris 2023
2023-06-08 • Epicentre Scientific Day Paris 2023
BACKGROUND
Patients with advanced HIV disease (AHD), defined as WHO clinical stage 3 or 4 and/or CD4<200, have a high risk of death. One common cause of death is invasive bacterial i...
Conference Material
|
Poster

Post-traumatic Pseudomonas aeruginosa osteomyelitis patients admitted to MSF orthopaedic centers in Mosul, Iraq and Gaza, Palestine: a retrospective study

Qasim A, Qasim A, Aqel R, Walker C, Moussally K,  et al.
2023-06-07 • MSF Scientific Day International 2023
2023-06-07 • MSF Scientific Day International 2023
Conference Material
|
Abstract

Treating post-trauma osteomyelitis cases in the conflict setting of Gaza: a retrospective cohort study

Aqel R
2022-06-01 • Epicentre Scientific Day Paris 2022
2022-06-01 • Epicentre Scientific Day Paris 2022
BACKGROUND
Post-traumatic osteomyelitis (PTO) is a serious consequence of orthopaedic trauma often complicated with multi-drug resistant (MDR) infections, a major health issue global...
Conference Material
|
Abstract

The antibiotic resistance patterns shown in an acute trauma hospital in Aden, Yemen from 2018 to June 2021

Malaeb R, Nagwan Y
2022-06-01 • Epicentre Scientific Day Paris 2022
2022-06-01 • Epicentre Scientific Day Paris 2022
BACKGROUND
Antimicrobial resistance (AMR) is a global health problem and growing at an alarming rate, resulting in a rapid deterioration of the effectiveness of antibiotics. The midd...
Journal Article
|
Research

The challenge of antibiotic resistance in post-war Mosul, Iraq: An analysis of 20 months microbiological samples from a tertiary orthopaedic care centre

M'Aiber S, Maamari K, Williams A, Albakry Z, Taher AQM,  et al.
2022-06-01 • Journal of Global Antimicrobial Resistance
2022-06-01 • Journal of Global Antimicrobial Resistance
BACKGROUND
Iraq has suffered unrest and conflicts in the past decades leaving behind a weakened healthcare system. In 2018, Médecins Sans Frontières (MSF) opened a tertiary orthopaed...
Journal Article
|
Research

When first line treatment of neonatal infection is not enough: blood culture and resistance patterns in neonates requiring second line antibiotic therapy in Bangui, Central African Republic

Nebbioso A, Ogundipe OF, Repetto EC, Mekiedje C, Sanke-Waigana H,  et al.
2021-12-13 • BMC Pediatrics
2021-12-13 • BMC Pediatrics
BACKGROUND
Infectious diseases account for the third most common cause of neonatal deaths. Globally, antibiotic resistance (ABR) has been increasingly challenging neonatal sepsis tre...
Journal Article
|
Research

Prevalence of MDR bacteria in an acute trauma hospital in Port-au-Prince, Haiti: a retrospective analysis from 2012 to 2018

Acma A, Williams A, Repetto EC, Cabral S, Sunyoto T,  et al.
2021-09-06 • JAC-Antimicrobial Resistance
2021-09-06 • JAC-Antimicrobial Resistance
BACKGROUND
Antibiotic resistance (ABR) is recognized as an increasing threat to global health. Haiti declared ABR an emerging public health threat in 2018, however, the current surve...
Journal Article
|
Research

Post-traumatic osteomyelitis in Middle East war-wounded civilians: resistance to first-line antibiotics in selected bacteria over the decade 2006-2016

Fily F, Ronat JB, Malou N, Kanapathipillai R, Seguin C,  et al.
2019-01-31 • BMC Infectious Diseases
2019-01-31 • BMC Infectious Diseases
BACKGROUND
War-wounded civilians in Middle East countries are at risk of post-traumatic osteomyelitis (PTO). We aimed to describe and compare the bacterial etiology and proportion of...

See more collections

Climate change and health

Climate change and health
The climate crisis is also a health and humanitarian crisis, disproportionately impacting people in the world’s most climate-sensitive regions—mainly low- and low-middle income countries with the least capacity to respond. MSF and other humanitarian organizations witness the consequences daily. More frequent, intense weather events and a warming planet contribute to food and water scarcity, more severe and widespread disease outbreaks, and more injuries and preventable deaths. They also drive massive population displacement, with over 32 million people fleeing their homes in 2022 alone due to floods, drought, storms and fire—nearly triple the number displaced by violence and conflict. As global leaders convene in Dubai for the UN climate conference (COP28, 30 Nov-12 Dec 2023) we present this cross-section of work by MSF and collaborators, drawing from first-hand experience at our medical projects. Emphasizing the urgency of adapting humanitarian operations to the climate crisis, the collection also explores loss and damage through a health lens, proposes policies and practices for creating climate-resilient health organizations, and advocates for embedding fair, just ethics perspectives into humanitarian action and research on climate.
Combatting antimicrobial resistance

Combatting antimicrobial resistance

Antimicrobial resistance is a growing public health crisis, especially in countries with fragile health systems, population displacement or ongoing conflict. In 2019 antibiotic-resistant bacteria directly caused an estimated 1.27 million deaths, and contributed to 4.95 million deaths, tolls that will continue to increase if no effective action is taken.


MSF’s approach to combatting antimicrobial resistance combines three pillars: infection prevention and control, microbiology and surveillance, and rational use of antibiotics via antibiotic stewardship. Several studies characterize patterns and prevalence of antibiotic resistance among MSF patients, from civilians wounded in Middle East conflicts to hospitalized neonates in Central African Republic and Haiti. New technologies developed by MSF and partners are expanding local capacity for rapid, accurate laboratory diagnosis of infections, so that clinicians can prescribe the right antibiotic for each patient. Other work assesses the practices and challenges related to optimizing rational antibiotic use within health facilities and communities.

If you're interested in learning more about MSF's work in antimicrobial resistance, view the full list of MSF's publications on the topic.

Snake envenoming: a neglected crisis

Snake envenoming: a neglected crisis

Every year 2 million or more people fall victim to snakebite envenoming, mostly in poor, rural communities of Africa, Asia and Latin America. Between 83,000—138,000 of them die, while hundreds of thousands more suffer debilitating long-term complications or disabilities.


Although some antivenom medicines are highly effective when used promptly and appropriately, many snakebite victims get no treatment at all. Those who do may receive antivenoms which don’t work against the type of snake that bit them, or were not rigorously tested for safety and effectiveness.


To mark World Snakebite Awareness Day on September 19th, the Collection linked below brings together recent MSF work on this highly neglected disease. Several articles and conference presentations help fill evidence gaps on the burden of disease and its impacts or on treatment outcomes with specific antivenoms in specific regions. Others examine how to tackle the formidable challenges of availability and affordability, the absence of regulatory oversight for making, testing and registering antivenoms, and the anemic R&D pipeline for new products—all of which impede access for patients to safe, effective treatment tailored to local snake species.

View All Collections